fax (330) 253-0201
FMI Medical Systems, Inc. (“FMI”) has developed an ultra high resolution diagnostic imaging technology that can be combined with drugs and molecular tracers for early detection and monitoring of neurodegenerative and cardiac disorders. FMI Medical Systems ScintiStar PET/CT systems offer a superior and cost effective imaging solution that enables advanced therapy. In addition, its unique Fused Multimodality Imaging will offer the data critical to earlier physician diagnosis of cardiac disease, neurodegenerative disorders, and cancers than are possible with current technology.
FMI systems are custom designed for specific diseases combining multiple common detection modalities – both structural and functional imaging (PET+CT).
Structural imaging provides information about the shape, position or volume of tissue.
Functional imaging reveals how well cells in various body regions are working by showing how actively the cells use sugar or oxygen and blood flow.
The technology breakthrough that FMI offers rests in its proprietary method for blending structural and functional imaging into a diagnostic tool that is 20%-25% of the cost of any single, currently available alternative.
William K. McCroskey
President and CEO of FMI Technologies, Inc.